Kamada (KMDA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $467.05M
Last updated: Nov 17, 2026 at 11:04 AM ET
Kamada (KMDA) Earnings: Report Dates and Results
Kamada (KMDA) is expected to report earnings on Mar 9, 2027. In the quarter ended Sep 30, 2026, Kamada reported EPS of $0.14, above the $0.13 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
KMDA has an expected report date of Mar 9, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 83.3% above the $0.06 reported for the quarter ended Dec 31, 2025.
KMDA Earnings Call
The latest KMDA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, KMDA beat 16, missed 17 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $51.07M, up 8.6% from $47.01M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.14 | $0.13 | $0.10 - $0.16 | +7.69% | Beat | +55.6% | 4 | 0 up, 1 down | Nov 9, 2026 | $51.07M |
| Jun 30, 2026 | $0.16 | $0.12 | $0.09 - $0.13 | +33.33% | Beat | +23.1% | 4 | 1 up, 1 down | Aug 12, 2026 | $54.92M |
| Mar 31, 2026 | $0.07 | $0.12 | $0.10 - $0.14 | -41.67% | Miss | 0.0% | 4 | 1 up, 1 down | May 13, 2026 | $45.24M |
| Dec 31, 2025 | $0.06 | $0.10 | $0.05 - $0.10 | -40.00% | Miss | -14.3% | 4 | 1 up, 0 down | Mar 11, 2026 | $44.68M |
| Sep 30, 2025 | $0.09 | $0.09 | $0.08 - $0.11 | 0.00% | In line | +28.6% | 4 | 1 up, 0 down | Nov 10, 2025 | $47.01M |
| Jun 30, 2025 | $0.13 | $0.09 | $0.08 - $0.11 | +44.44% | Beat | +62.5% | 4 | 2 up, 0 down | Aug 13, 2025 | $44.75M |
| Mar 31, 2025 | $0.07 | $0.07 | $0.06 - $0.07 | 0.00% | In line | +75.0% | 4 | 0 up, 0 down | May 14, 2025 | $44.02M |
| Dec 31, 2024 | $0.07 | $0.05 | $0.04 - $0.07 | +31.33% | Beat | -22.2% | 3 | 0 up, 0 down | Mar 5, 2025 | $39.01M |
| Sep 30, 2024 | $0.07 | $0.07 | $0.06 - $0.07 | 0.00% | In line | +16.7% | 3 | 0 up, 0 down | Nov 13, 2024 | $41.74M |
| Jun 30, 2024 | $0.08 | $0.06 | $0.05 - $0.06 | +33.33% | Beat | +100.0% | 3 | 0 up, 0 down | Aug 14, 2024 | $42.47M |
| Mar 31, 2024 | $0.04 | $0.07 | $0.05 - $0.07 | -42.86% | Miss | N/A | 2 | 0 up, 0 down | May 8, 2024 | $37.74M |
| Dec 31, 2023 | $0.09 | $0.05 | $0.04 - $0.06 | +80.00% | Beat | +28.6% | 2 | 0 up, 0 down | Mar 6, 2024 | $36.43M |
| Sep 30, 2023 | $0.06 | $0.02 | $0.02 - $0.04 | +200.00% | Beat | +20.0% | 2 | 0 up, 0 down | Nov 13, 2023 | $37.93M |
| Jun 30, 2023 | $0.04 | $0.03 | $0.01 - $0.03 | +33.33% | Beat | N/A | 2 | 0 up, 0 down | Aug 16, 2023 | $37.44M |
| Mar 31, 2023 | -$0.04 | $0.04 | $0.01 - $0.04 | -200.00% | Miss | N/A | 2 | 0 up, 0 down | May 24, 2023 | $30.71M |
| Dec 31, 2022 | $0.07 | $0.07 | $0.04 - $0.09 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Mar 15, 2023 | $45.44M |
| Sep 30, 2022 | $0.05 | -$0.03 | -$0.03 - -$0.03 | +266.67% | Beat | N/A | 1 | 0 up, 0 down | Nov 22, 2022 | $32.22M |
| Jun 30, 2022 | -$0.05 | -$0.02 | N/A | -150.00% | Miss | -350.0% | N/A | N/A | Aug 17, 2022 | $23.59M |
| Mar 31, 2022 | -$0.04 | $0.03 | N/A | -233.33% | Miss | -180.0% | N/A | N/A | May 17, 2022 | $28.09M |
| Dec 31, 2021 | -$0.11 | -$0.01 | -$0.02 - $0.02 | -1000.00% | Miss | -375.0% | 2 | 0 up, 0 down | Mar 15, 2022 | $31.47M |
| Sep 30, 2021 | -$0.02 | $0.02 | $0.02 - $0.03 | -200.00% | Miss | -113.3% | 2 | 0 up, 0 down | Nov 22, 2021 | $23.03M |
| Jun 30, 2021 | $0.02 | $0.06 | $0.04 - $0.06 | -66.67% | Miss | -75.0% | 2 | N/A | Aug 11, 2021 | $24.24M |
| Mar 31, 2021 | $0.05 | $0.07 | $0.02 - $0.18 | -28.57% | Miss | -58.3% | 3 | N/A | May 12, 2021 | $24.90M |
| Dec 31, 2020 | $0.04 | $0.10 | $0.04 - $0.10 | -60.00% | Miss | -66.7% | 3 | N/A | Feb 10, 2021 | $31.54M |
| Sep 30, 2020 | $0.15 | $0.09 | $0.03 - $0.09 | +66.67% | Beat | +7.1% | 3 | N/A | Nov 11, 2020 | $35.33M |
| Jun 30, 2020 | $0.08 | $0.12 | $0.09 - $0.12 | -33.33% | Miss | -46.7% | 3 | N/A | Aug 12, 2020 | $33.09M |
| Mar 31, 2020 | $0.12 | $0.05 | $0.04 - $0.10 | +140.00% | Beat | 0.0% | 3 | N/A | May 18, 2020 | $33.29M |
| Dec 31, 2019 | $0.12 | $0.14 | $0.11 - $0.14 | -14.29% | Miss | -73.3% | 3 | N/A | Feb 12, 2020 | $32.07M |
| Sep 30, 2019 | $0.14 | $0.09 | $0.05 - $0.09 | +55.56% | Beat | N/A | 3 | N/A | Nov 13, 2019 | $33.07M |
| Jun 30, 2019 | $0.15 | $0.17 | $0.12 - $0.17 | -11.76% | Miss | +7.1% | 3 | N/A | Aug 6, 2019 | $35.25M |
| Mar 31, 2019 | $0.12 | $0.01 | $0.01 - $0.08 | N/A | N/A | +300.0% | 3 | N/A | May 14, 2019 | $26.80M |
| Dec 31, 2018 | $0.45 | $0.19 | $0.11 - $0.23 | +136.84% | Beat | +181.3% | 3 | N/A | Feb 12, 2019 | $48.21M |
| Sep 30, 2018 | -$0.06 | -$0.02 | N/A | -200.00% | Miss | N/A | N/A | N/A | Nov 12, 2018 | $14.97M |
| Jun 30, 2018 | $0.14 | $0.04 | N/A | +250.00% | Beat | +7.7% | 2 | N/A | Aug 7, 2018 | $33.84M |
| Mar 31, 2018 | $0.03 | $0.04 | $0.00 - $0.04 | -25.00% | Miss | N/A | 3 | N/A | May 15, 2018 | $17.44M |
| Dec 31, 2017 | $0.16 | $0.10 | $0.06 - $0.10 | +60.00% | Beat | N/A | 2 | N/A | Feb 7, 2018 | $35.71M |
| Sep 30, 2017 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | 1 | N/A | Nov 13, 2017 | $22.92M |
| Jun 30, 2017 | $0.13 | $0.13 | $0.10 - $0.13 | 0.00% | In line | N/A | 2 | N/A | Aug 1, 2017 | $32.55M |
| Mar 31, 2017 | -$0.11 | -$0.02 | -$0.05 - $0.00 | -450.00% | Miss | N/A | 2 | N/A | May 16, 2017 | $11.65M |
| Dec 31, 2016 | -$0.05 | -$0.09 | N/A | +44.44% | Beat | -266.7% | N/A | N/A | Feb 6, 2017 | $24.26M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.35, up 34.6% from the year before. It was -$0.15 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.35 | +34.6% |
| Dec 31, 2024 | $0.26 | +73.3% |
| Dec 31, 2023 | $0.15 | +400.0% |
| Dec 31, 2022 | $0.03 | N/A |
| Dec 31, 2021 | -$0.06 | -115.4% |
| Dec 31, 2020 | $0.39 | -26.4% |
| Dec 31, 2019 | $0.53 | N/A |
| Dec 31, 2018 | $0.56 | +229.4% |
| Dec 31, 2017 | $0.17 | N/A |
| Dec 31, 2016 | -$0.15 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,100 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,054 | 6 | |
| 2026Q2 | Jun 30, 2026 | 3,387 | 6 | |
| 2026Q1 | Mar 31, 2026 | 3,041 | 6 | |
| 2025Q4 | Dec 31, 2025 | 3,451 | 7 | |
| 2025Q3 | Sep 30, 2025 | 3,762 | 6 | |
| 2025Q2 | Jun 30, 2025 | 3,146 | 6 | |
| 2025Q1 | Mar 31, 2025 | 2,777 | 6 | |
| 2024Q3 | Sep 30, 2024 | 2,767 | 5 |
2026Q3 Earnings Call
Opening remarks
Brian Ritchie Managing Director, LifeSci Advisors Thank you, Operator. This is Brian Ritchie with LifeSci Advisors. Thank you all for participating in today's call. Joining me from Kamada are Amir London, Chief Executive Officer, and Chaime Orlev, Chief Financial Officer. Earlier today, Kamada announced its financial results for the 3 and 9 months ended September 30, 2026. If you have not received this news release, please go to the Investors page of the company's website at kamada.com. Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Kamada. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, the company's Forms 20-F and 6-K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Monday, November 9, 2026. Kamada undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. With that said, it is my pleasure to turn the call over to Amir London, CEO. Amir.
Amir London CEO Thank you, Brian. My thanks also to our investors and analysts for your interest in Kamada and for participating in today's call. During the third quarter of 2026, we continued with the strong operational and financial performance we demonstrated throughout the year, with double-digit growth in revenues and adjusted EBITDA for both the third quarter and the 9-month reporting period. Based on our excellent performance, we are increasing our 2026 annual guidance, and we are projecting continued double-digit profitable growth during 2027. Total revenues for the 9-month period were a record of $152.2 million, an increase of approximately 12% year-over-year. Adjusted EBITDA was $40.9 million, up 20% year-over-year, and representing a 27% margin of revenues, and net income totaled $21.4 million, up 29% year-over-year. The underlying demand for our products, especially KEDRAB in the U.S. market, as well as VARIZIG and HEPAGAM, continues to expand. We are also pleased to announce another cash dividend of $0.14 per share for a total payment of approximately $8 million to be paid to our shareholders during the fourth quarter of this year. This is in addition to the $24.2 million dividend payments already made earlier this year, bringing the total dividend in 2026 to approximately $32.3 million. Our ability to continue paying dividends while maintaining our strong cash position and continuing to invest in commercial growth is indicative of our excellent financial and operational performance.
Frequently Asked Questions About KMDA
When is Kamada's next earnings date?
Kamada's next earnings report is expected for Mar 9, 2027.
Did KMDA beat earnings estimates last quarter?
Yes. Kamada reported EPS of $0.14 for the quarter ended Sep 30, 2026, above the $0.13 estimate, a 7.69% surprise.
What EPS do analysts expect from KMDA next quarter?
The consensus EPS estimate for Kamada for the quarter ending Dec 31, 2026 is $0.11 from 6 analysts, with estimates from $0.09 to $0.14.
How often does KMDA beat earnings estimates?
Kamada beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +4.39%.
KMDA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors